IRIS
FARINA, DEBORAH
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.613
EU - Europa 1.339
AS - Asia 835
SA - Sud America 57
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 1
OC - Oceania 1
Totale 3.851
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.607
CN - Cina 359
UA - Ucraina 255
IE - Irlanda 254
SG - Singapore 213
TR - Turchia 177
GB - Regno Unito 176
SE - Svezia 168
FR - Francia 131
IT - Italia 126
DE - Germania 96
FI - Finlandia 61
IN - India 57
BR - Brasile 51
RU - Federazione Russa 39
CZ - Repubblica Ceca 13
IR - Iran 10
HK - Hong Kong 7
CH - Svizzera 6
BE - Belgio 5
EU - Europa 5
MX - Messico 4
AR - Argentina 2
CA - Canada 2
GR - Grecia 2
KR - Corea 2
PY - Paraguay 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
EG - Egitto 1
HR - Croazia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LB - Libano 1
MD - Moldavia 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.851
Salva come PNG Salva come JPEG
Città #
Chandler 323
Jacksonville 307
Dublin 253
Southend 152
Singapore 150
Princeton 108
The Dalles 99
Izmir 92
Nanjing 89
Beijing 79
Ashburn 68
Dearborn 58
Wilmington 58
Cambridge 49
Altamura 37
Nanchang 33
Santa Clara 33
New York 30
Ann Arbor 28
Shenyang 21
Chieti 16
Washington 15
Hebei 14
Jiaxing 14
Kunming 14
Tianjin 14
Boardman 13
Hangzhou 13
Woodbridge 13
Brno 12
Changsha 12
Grevenbroich 12
Helsinki 11
Jinan 11
Los Angeles 11
Norwalk 10
Guangzhou 9
Ardabil 8
Augusta 8
Monmouth Junction 8
Camerino 7
Hong Kong 7
San Mateo 7
Campobasso 6
Fribourg 6
Houston 6
Lanzhou 6
Brussels 5
Leawood 5
Ningbo 5
Changchun 4
Montesilvano Marina 4
Taizhou 4
Teramo 4
Ankara 3
Curitiba 3
London 3
Mumbai 3
Munich 3
Orange 3
San Vito Chietino 3
São Paulo 3
Tappahannock 3
Torino 3
Zhengzhou 3
Belgrade 2
Belo Horizonte 2
Bologna 2
Campo Grande 2
Düsseldorf 2
Edinburgh 2
Florence 2
Frankfurt am Main 2
Hanover 2
Isernia 2
Istanbul 2
Mexico City 2
Moscow 2
Naples 2
Nuremberg 2
Palermo 2
Palo Alto 2
Paulínia 2
Pelotas 2
Pescara 2
Rio de Janeiro 2
Rome 2
Walnut 2
Aachen 1
Americana 1
Amman 1
Andover 1
Antakya 1
Aparecida de Goiânia 1
Araçoiaba da Serra 1
Ascoli Piceno 1
Asunción 1
Atlanta 1
Auburn Hills 1
Baghdad 1
Totale 2.472
Salva come PNG Salva come JPEG
Nome #
A lipidomic investigation for the caracterisation of CSF lipid profile in patients with multiple sclerosis 107
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 102
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 100
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 96
Increasing age at disability milestones among MS patients in the MSBase Registry 95
Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center 95
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 94
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 92
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 91
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. 87
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 85
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 85
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 84
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 83
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 83
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients 83
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 81
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 80
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 79
Cognitive dysfunction in patients with relapsing-remitting Multiple Sclerosis 78
Brain tissue loss occurs after suppression of enhancement in patients with multiple scerosis treated with autologous haematopoietic stem cell transplantation. 77
Interferone beta: effetti collaterali 76
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 76
JCV-Ab serostatus in MS patients treated with Natalizumab 75
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 75
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 74
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 74
Natalizumab-associated PML-IRIS: the Chieti experience. 73
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 73
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 72
Mass spectrometry based metabonomics of the cerebrospinalfluid highlights a correlation between polar lipids and carnitines levels in multiple sclerosis patients. 72
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 71
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 68
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 68
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial 67
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 67
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. 67
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis 66
Autologous HSCT for severe progressive Multiple Sclerosis in a multicenter trial: impact on disease activity and quality of life 66
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 66
Interferone beta1b: bilancio su un gruppo di 30 pazienti 65
Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study 63
Lymphomononuclear cells from multiple scerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors alpha and beta, and interferon gamma. 62
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 61
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 60
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 59
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study 57
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis 53
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 50
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis 49
Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis 49
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 44
Long-term efficacy and tolerability of natalizumab treatment in multiple sclerosis patients: a multicentre experience in Italy 40
Totale 3.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.913
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202093 0 0 0 0 0 0 0 0 0 0 88 5
2020/2021317 52 2 58 0 17 63 2 3 34 29 47 10
2021/2022213 1 4 6 49 6 2 6 19 12 3 31 74
2022/2023806 58 122 45 83 86 164 40 56 108 6 23 15
2023/2024397 34 18 25 6 29 164 72 3 1 7 2 36
2024/2025573 60 99 111 13 13 31 19 31 62 43 91 0
Totale 3.915